Browse our publications

All Titles empty
Stockley's Drug Interactions: A source book of interactions, their mechanisms, clinical importance and management

Stockley's Drug Interactions: A source book of interactions, their mechanisms, clinical importance and management

NEW 11th EDITION

Edition: 11th Edition

Details: Hardback.

List Price (RRP): £205.00 (No VAT Payable)Save £20.50 with our 10.0% online discountOur Online Price: £184.50

NOW IN STOCK FOR NEXT-DAY DELIVERY

Publication date: 01/03/2016

Publisher: Pharmaceutical Press

ISBN: 9780857112705

Publication Status: Active

or

Stockley’s Drug Interactions, edited by Claire L Preston, remains the world’s most comprehensive and authoritative international reference book on drug interactions. Based upon thousands of published papers and reports this eleventh edition:

  • Covers interactions between therapeutic drugs, proprietary medicines, herbal medicines, foods, drinks, and drugs of abuse
  • Contains in-depth yet concise monographs in an easy-to-read format
  • Provides comprehensive details of the clinical evidence for the interactions under discussion, an assessment of their clinical importance, and clear guidance on managing the interaction in practice
  • Has a brief summary of the interaction in each monograph – perfect for the busy healthcare professional
  • Is fully referenced throughout
  • Contains almost 4500 monographs
  • Is global in coverage – inclusion of drugs used worldwide

New in the 11th edition:
  • Over 350 new monographs added
  • Many existing monographs have been reviewed, revalidated, and updated
  • A comprehensive update and restructure of the chapter on Antidiabetic drugs, in-line with published literature
  • Addition of new advice regarding the concurrent use of aliskiren, ACE inhibitors, and angiotensin-II receptor antagonists
  • An updated list of drugs that have a risk of prolonging the QT interval
  • The addition of new drugs, including apixaban, apremilast, dolutegravir, lomitapide, mirabegron, the NS5A inhibitors (daclatasvir, ledipasvir, ombitasvir), the NS5B inhibitors (dasabuvir, sofosbuvir), the sodium-glucose co-transporter-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), and telavancin

Back